LOX-1 boosts immunity

Lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) is a class E scavenger receptor that is encoded by the OLR1 gene on human chromosome 12. LOX-1 is expressed as a type II transmembrane protein containing four domains: an extracellular C-terminal lectin domain, a connecting neck domain, a single transcellular domain and a short N-terminal cytoplasmic tail. A disulfide bond between monomers at cysteine 140 residues results in the formation of a LOX-1 homodimer. LOX-1 is expressed on the surface of endothelial cells as well as several other cell types, including smooth muscle cells, platelets, and fibroblasts. LOX-1 is also expressed on the surface of other immune cells, such as dendritic cells (DCs) and macrophages. The expression level of LOX-1 can be modulated by inflammatory stimuli as well as by its ligands. Proteolytic cleavage at the neck domain also forms a soluble LOX-1. Despite lacking the classical signaling motifs, LOX-1 can induce and modulate cell activation via membrane-bound nicotinamide adenine dinucleotide phosphate oxidase followed by the generation of reactive oxygen species that can further activate nuclear factor-κB [1]. Multiple other signaling components, such as phosphoinositide 3-kinase, p38 mitogen-activated protein kinase and protein kinase C, are also known to be involved in LOX-1-induced signaling pathways [1]. LOX-1-mediated internalization of oxidized LDL occurs through a clathrin-independent mechanism involving a novel cytoplasmic tripeptide receptor motif [2]. LOX-1 can thus display multiple cellular functions, including cytokine production and apoptosis-associated cell death as well as endocytosis and phagocytosis. Due to its expression on vascular endothelial cells and its unique ability to capture oxidized-LDL, C-reactive protein (CRP), and fibronectin, studies on LOX-1 have been mainly focused on its roles in the pathogenesis of vascular diseases (e.g., atherosclerosis). Nonetheless, the roles of LOX-1 in host immune responses remain largely unknown, although one could assume that LOX-1 expressed on antigen presenting cells, particularly DCs, could contribute to host immune responses in either a healthy or diseased condition or in both. This assumption is particularly relevant because DCs are major immune inducers and orchestrators and can thus play key roles in host immunity against cancers and infections as well as in autoimmune diseases. It was interesting to find that LOX-1 is expressed on CD1c + skin dermal DCs and blood myeloid DCs but not Langerhans cells or plasmacytoid DCs in humans [3, 4]. Not all, but only fractions of peripheral B cells and monocytes also expressed LOX-1 [4]. Furthermore, antigen targeting …